{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:13:37Z","timestamp":1767986017233,"version":"3.49.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK118354"],"award-info":[{"award-number":["R01DK118354"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>The identification of surrogate markers is motivated by their potential to make decisions sooner about a treatment effect. However, few methods have been developed to actually use a surrogate marker to test for a treatment effect in a future study. Most existing methods consider combining surrogate marker and primary outcome information to test for a treatment effect, rely on fully parametric methods where strict parametric assumptions are made about the relationship between the surrogate and the outcome, and\/or assume the surrogate marker is measured at only a single time point. Recent work has proposed a nonparametric test for a treatment effect using only surrogate marker information measured at a single time point by borrowing information learned from a prior study where both the surrogate and primary outcome were measured. In this paper, we utilize this nonparametric test and propose group sequential procedures that allow for early stopping of treatment effect testing in a setting where the surrogate marker is measured repeatedly over time. We derive the properties of the correlated surrogate-based nonparametric test statistics at multiple time points and compute stopping boundaries that allow for early stopping for a significant treatment effect, or for futility. We examine the performance of our proposed test using a simulation study and illustrate the method using data from two distinct AIDS clinical trials.<\/jats:p>","DOI":"10.1093\/biomtc\/ujae108","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T16:01:58Z","timestamp":1728403318000},"source":"Crossref","is-referenced-by-count":2,"title":["Group sequential testing of a treatment effect using a surrogate marker"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7288-1009","authenticated-orcid":false,"given":"Layla","family":"Parast","sequence":"first","affiliation":[{"name":"Department of Statistics and Data Sciences, The University of Texas at Austin , Austin, TX 78712 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Bartroff","sequence":"additional","affiliation":[{"name":"Department of Statistics and Data Sciences, The University of Texas at Austin , Austin, TX 78712 ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"2025010313110465500_bib1","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1287\/mnsc.2021.4096","article-title":"Adaptive clinical trial designs with surrogates: When should we bother?","volume":"68","author":"Anderer","year":"2022","journal-title":"Management Science"},{"key":"2025010313110465500_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-6114-2","volume-title":"Sequential Experimentation in Clinical Trials: Design and Analysis","author":"Bartroff","year":"2013"},{"key":"2025010313110465500_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1467-9868.2007.00617.x","article-title":"Criteria for surrogate end points","volume":"69","author":"Chen","year":"2007","journal-title":"Journal of the Royal Statistical Society Series B: Statistical Methodology"},{"key":"2025010313110465500_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/bimj.4710380112","article-title":"Incorporating surrogate endpoints into group sequential trials","volume":"38","author":"Cook","year":"1996","journal-title":"Biometrical Journal"},{"key":"2025010313110465500_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1146\/annurev-statistics-032921-035359","article-title":"Surrogate endpoints in clinical trials","volume":"10","author":"Elliott","year":"2023","journal-title":"Annual Review of Statistics and its Application"},{"key":"2025010313110465500_bib6","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/biostatistics\/kxu043","article-title":"Surrogacy marker paradox measures in meta-analytic settings","volume":"16","author":"Elliott","year":"2015","journal-title":"Biostatistics"},{"key":"2025010313110465500_bib7","volume-title":"Surrogate endpoint resources for drug and biologic development","author":"FDA","year":"2023"},{"key":"2025010313110465500_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/sim.4780110204","article-title":"Statistical validation of intermediate endpoints for chronic diseases","volume":"11","author":"Freedman","year":"1992","journal-title":"Statistics in Medicine"},{"key":"2025010313110465500_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199709113371101","article-title":"A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and cd4 cell counts of 200 per cubic millimeter or less","volume":"337","author":"Hammer","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"2025010313110465500_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00042560-199812010-00004","article-title":"A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced aids","volume":"19","author":"Henry","year":"1998","journal-title":"Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology"},{"key":"2025010313110465500_bib11","volume-title":"Group Sequential Methods with Applications to Clinical Trials","author":"Jennison","year":"2000"},{"key":"2025010313110465500_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0378-3758(00)00339-6","article-title":"On group sequential tests for data in unequally sized groups and with unknown variance","volume":"96","author":"Jennison","year":"2001","journal-title":"Journal of Statistical Planning and Inference"},{"key":"2025010313110465500_bib13","first-page":"0223","article-title":"Independent increments in group sequential tests: a review","volume":"44","author":"Kim","year":"2020","journal-title":"SORT: Statistics and Operations Research Transactions"},{"key":"2025010313110465500_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1109\/TPAMI.2019.2945942","article-title":"A Review of Domain Adaptation Without Target Labels","volume":"43","author":"Kouw","year":"2019","journal-title":"IEEE Transactions on Pattern Analysis and Machine Intelligence"},{"key":"2025010313110465500_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/19466315.2021.1938203","article-title":"Using surrogate endpoints in adaptive designs with delayed treatment effect","volume":"14","author":"Li","year":"2022","journal-title":"Statistics in Biopharmaceutical Research"},{"key":"2025010313110465500_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/biomet\/78.1.123","article-title":"Nonparametric sequential testing in clinical trials with incomplete multivariate observations","volume":"78","author":"Lin","year":"1991","journal-title":"Biometrika"},{"key":"2025010313110465500_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2307\/2530245","article-title":"A multiple testing procedure for clinical trials","volume":"35","author":"O\u2019Brien","year":"1979","journal-title":"Biometrics"},{"key":"2025010313110465500_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-3758(94)90187-2","article-title":"Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis","volume":"42","author":"Pampallona","year":"1994","journal-title":"Journal of Statistical Planning and Inference"},{"key":"2025010313110465500_bib19","volume-title":"Surrogateseq r package, version 1.0","author":"Parast","year":"2024"},{"key":"2025010313110465500_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/sim.7220","article-title":"Evaluating surrogate marker information using censored data","volume":"36","author":"Parast","year":"2017","journal-title":"Statistics in Medicine"},{"key":"2025010313110465500_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/biom.13067","article-title":"Using a surrogate marker for early testing of a treatment effect","volume":"75","author":"Parast","year":"2019","journal-title":"Biometrics"},{"key":"2025010313110465500_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/sim.9602","article-title":"Using a surrogate with heterogeneous utility to test for a treatment effect","volume":"42","author":"Parast","year":"2023","journal-title":"Statistics in Medicine"},{"key":"2025010313110465500_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/biomet\/64.2.191","article-title":"Group sequential methods in the design and analysis of clinical trials","volume":"64","author":"Pocock","year":"1977","journal-title":"Biometrika"},{"key":"2025010313110465500_bib24","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/biom.12879","article-title":"Estimation of the optimal surrogate based on a randomized trial","volume":"74","author":"Price","year":"2018","journal-title":"Biometrics"},{"key":"2025010313110465500_bib25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/pst.2298","article-title":"Utilization of treatment effect on a surrogate endpoint for planning a study to evaluate treatment effect on a final endpoint","volume":"22","author":"Quan","year":"2023","journal-title":"Pharmaceutical Statistics"},{"key":"2025010313110465500_bib26","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/sim.8060","article-title":"Predictive probability of success using surrogate endpoints","volume":"38","author":"Saint-Hilary","year":"2019","journal-title":"Statistics in Medicine"},{"key":"2025010313110465500_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3390\/stats6010020","article-title":"Incorporating covariates into measures of surrogate paradox risk","volume":"6","author":"Shafie\u00a0Khorassani","year":"2023","journal-title":"Stats"},{"key":"2025010313110465500_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/096228020000900506","article-title":"An overview of group sequential methods in longitudinal clinical trials","volume":"9","author":"Spiessens","year":"2000","journal-title":"Statistical Methods in Medical Research"},{"key":"2025010313110465500_bib29","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/01621459.1989.10478836","article-title":"Design of group sequential clinical trials with multiple endpoints","volume":"84","author":"Tang","year":"1989","journal-title":"Journal of the American Statistical Association"},{"key":"2025010313110465500_bib30","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"},{"key":"2025010313110465500_bib31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/biom.12071","article-title":"Surrogate measures and consistent surrogates","volume":"69","author":"VanderWeele","year":"2013","journal-title":"Biometrics"},{"key":"2025010313110465500_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/EDE.0b013e3181f74493","article-title":"Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders","volume":"22","author":"VanderWeele","year":"2011","journal-title":"Epidemiology"},{"key":"2025010313110465500_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2307\/2531959","article-title":"Approximately optimal one-parameter boundaries for group sequential trials","volume":"43","author":"Wang","year":"1987","journal-title":"Biometrics"},{"key":"2025010313110465500_bib34","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.0006-341X.2002.00803.x","article-title":"A measure of the proportion of treatment effect explained by a surrogate marker","volume":"58","author":"Wang","year":"2002","journal-title":"Biometrics"},{"key":"2025010313110465500_bib35","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/sim.4273","article-title":"Sufficient conditions for concluding surrogacy based on observed data","volume":"30","author":"Wu","year":"2011","journal-title":"Statistics in Medicine"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/80\/4\/ujae108\/61199669\/ujae108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/80\/4\/ujae108\/61199669\/ujae108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T13:11:24Z","timestamp":1735909884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/doi\/10.1093\/biomtc\/ujae108\/7815645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/biomtc\/ujae108","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,3]]},"article-number":"ujae108"}}